One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: A systematic review

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 5, 2007, Pages 647-655

  Correll, Christoph U ^a,b   Kane, John M ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ADOLESCENT DISEASE; ARTICLE; AUTISM; BIPOLAR DISORDER; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CLINICAL TRIAL; DISRUPTIVE BEHAVIOR; DRUG INDICATION; HUMAN; INCIDENCE; META ANALYSIS; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DATA INTERPRETATION, STATISTICAL; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS;

EID: 35848970571     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0117     Document Type: Article

References (33)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE: Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843, 1997.
3. Chouinard G, Ross-Chouinard A, Annabel L, Jones BD: The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7:233, 1980.
4. Connor DF, Fletcher KE, Wood JS: Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62:967-974, 2001.
5. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA: Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 6:79-83, 2006.
6. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
7. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-425, 2004.
8. Correll CU, Penzner JB, Parikh UH, Mughal TB, Javed T, Carbon M, Malhotra AK: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177-206, 2006.
9. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ: A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531-1536, 2004.
10. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S, Risperidone Disruptive Behavior Study Group: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64-72, 2005.
11. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B, Risperidone Disruptive Behavior Study Group: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
12. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
13. Ghaemi SN, Hsu DJ, Rosenquist KJ, Pardo TB, Goodwin FK: Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:209-213, 2006.
14. Glazer WM: Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 61(Suppl 4)21-26, 2000.
15. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ABM 76-338. Washington (DC), US Department of Health, Education, and Welfare, 1976, pp 534-537.
16. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand SL, Rochon PA: Antipsychotic medications and drug-induced movement disorders other than parkinsonism: A population-based cohort study in older adults. J Am Geriatr Soc 53:1374-1379, 2005.
17. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 50:541-547.
18. Masi G, Mucci M, Millepiedi S: Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 12:93-99, 2002.
19. Masi G, Cosenza A, Mucci M, Brovedani P: A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 64:1039-1047, 2003.
20. Masi G, Milone A, Canepa G, Millepiedi S, Mucci M, Muratori F: Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry 21:51-57, 2006.
21. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K: Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial. J Child Adolesc Psychopharmacol 13:75-82, 2003.
22. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R: Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: An open-label study. J Child Adolesc Psychopharmacol 13:311-317, 2003.
23. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006.
24. Patel NC, Crismon ML, Shafer A: Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother 40:205-211, 2006.
25. Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG: A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 16:336-350, 2006.
26. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M: Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260-272, 2006a.
27. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M: Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 15:97-104, 2006b.
28. Ross RG, Novins D, Farley GK, Adler LE: A 1-year openlabel trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301-309, 2003.
29. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436, 2004.
30. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487, 1982.
31. Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, Bird ED, Riederer P, Jellinger K, Watanabe S, et al: Human brain dopamine receptors in children and aging adults. Synapse 1:399-404, 1987.
32. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004.
33. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.